HBM HOLDINGS-B (02142) opened more than 3% higher following a positive profit alert. At the time of writing, the stock was up 3.44% to HK$11.44, with a turnover of HK$480,500. On February 4, HBM HOLDINGS-B issued an announcement forecasting a profit for the year ending December 31, 2025, of between approximately $88 million (equivalent to about HK$685 million) and approximately $95 million (equivalent to about HK$739 million), compared to a profit of about $2.7 million for the year ended December 31, 2024. The expected adjusted total profit is projected to be between $91 million (equivalent to about HK$708 million) and $98 million (equivalent to about HK$763 million). The announcement stated that the anticipated increase in profit is primarily attributable to the company's sustained growth in recurring revenue, such as research collaborations based on its platform with AstraZeneca and Bristol-Myers Squibb. The rapid expansion of its global partner network, driven by income from out-licensing innovative products and collaborations that has been converted into recurring revenue streams, such as licensing agreements with Otsuka Pharmaceutical and Windward Bio. The rapid business growth of Nona Biotechnology, including revenue from technology licensing and platform-based services, as well as milestone payments from existing collaborations, such as the research and technology licensing collaboration with Pfizer.